Impact Of A Remote Centralized Heart Failure Management Program On Guideline-directed Medical Therapy Prescribing To Patients With Heart Failure With Reduced Ejection Fraction At A Multi-hospital Academic Health System
Matthew R. Carey,Erica Lancet,Shudhanshu Alishetti,Reema Bhatt,Edward F. Lin,Daniel Oren,Momina Iftikhar,Sonia Huang,Julianne Vasconcellos,Emily Webb,Danielle Fisher,Gabriel T. Sayer,Nir Uriel,Kelly Axsom
DOI: https://doi.org/10.1016/j.cardfail.2023.10.347
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Despite evidence demonstrating the impact of guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF) on outcomes, including mortality and heart failure hospitalizations, adoption and up-titration of such medications remain suboptimal. We examined the effectiveness of a remote centralized heart failure management program (CHFMP) on prescribing of GDMT in patients with HFrEF. Hypothesis We hypothesized that a remote CHFMP would increase prescribing of GDMT, both in terms of number of agents employed and doses of specific medications. Methods A remote CHFMP was established in 2020 to assist primary providers across a complex urban academic medical center in managing patients with heart failure (HF). In one sub-program, the medication optimization program (MOP), a remote team of physician assistants and a HF physician prescribed GDMT to patients with HFrEF. Physician assistants used remote monitoring data (e.g., blood pressure, weights, and labs) to guide the prescription of therapeutic agents and up-titrating doses using guidelines created by a multidisciplinary team. Patients graduated from the program after meeting pre-specified criteria. Number of GDMT medications and doses were compared between the first and last visits for all patients who graduated using Fisher's exact test and Wilcoxon rank-sum test, where appropriate. Results A total of 289 patients were enrolled for at least 30 days across 5 hospitals and graduated from the MOP between May 5, 2020 and December 20, 2022. Patients were enrolled for a median of 187 days (IQR 106-252 days). Median age was 60 years (IQR 50-71), and 196 (67.8%) were male. Figure A shows the increase in prescribing of several GDMT agents from the first to last visits for patients who graduated from the MOP. There was increased prescribing of mineralocorticoid receptor antagonists (MRAs) and sodium/glucose cotransporter-2 inhibitors (SGLT2is) (p<0.001 for both). Doses increased for sacubitril-valsartan, carvedilol, and metoprolol succinate from the first to the last visits among patients receiving those medications at the time of enrollment (Figure B, p<0.001 for all). For patients who did not reach target doses, hypotension (56 patients, 19.4%) and hyperkalemia (31 patients, 10.7%) were the most common limiting factors. Conclusions A remote CHFMP increased prescribing of GDMT to patients with HFrEF, driven by increases in MRA and SGLT2i prescribing as well as dose escalation.
cardiac & cardiovascular systems